{rfName}
Re

Indexed in

License and use

Altmetrics

Grant support

Biogen International GmbH (Baar, Switzerland)

Analysis of institutional authors

Chaparro Sanchez, MariaAuthorMartínez-Pérez TjAuthorBosch OAuthor

Share

April 25, 2023
Publications
>
Article
No

Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

Publicated to:ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 58 (1): 60-70 - 2023-04-23 58(1), DOI: 10.1111/apt.17525

Authors: Jose Casanova, Maria; Nantes, Oscar; Varela, Pilar; Vela-Gonzalez, Milagros; Rivero, Montserrat; Sierra-Gabarda, Olivia; Riestra, Sabino; Barreiro-de Acosta, Manuel; del Mar Martin-Rodriguez, Maria; Jerusalen Gargallo-Puyuelo, Carla; Reygosa, Cristina; Munoz, Roser; Garcia de la Filia-Molina, Irene; Nunez-Ortiz, Andrea; Kolle, Lilyan; Calafat, Margalida; Maria Huguet, Jose; Iglesias-Flores, Eva; de Jesus Martinez-Perez, Teresa; Bosch, Orencio; Maria Duque-Alcorta, Jose; Frago-Larramona, Santiago; Van Domselaar, Manuel; Manuel Gonzalez-Cosano, Victor; Bujanda, Luis; Garcia-Lopez, Santiago; de Francisco, Ruth; Nieto-Garcia, Laura; Laredo, Viviana; Gutierrez-Casbas, Ana; Mesonero, Francisco; Canete, Fiorella; Rodriguez, Cristina; Chaparro, Maria; Gisbert, Javier P

Affiliations

CIBERehd, Alicante, Spain - Author
CIBERehd, Badalona, Spain - Author
CIBEREHD, Donostia San Sebastian, Spain - Author
CIBERehd, Zaragoza, Spain - Author
Complejo Hospitalario Universitario de Granada - Author
Consorcio Hosp Gen Univ Valencia, Gastroenterol Dept, Valencia, Spain - Author
Fdn Jimenez Diaz, Gastroenterol Dept, Madrid, Spain - Author
Fundación Jiménez Díaz - Author
Hosp Clin Lozano Blesa, Inst Invest Sanitaria Aragon, Gastroenterol Dept, Zaragoza, Spain - Author
Hosp Clin Univ Santiago Compostela, Gastroenterol Dept, Santiago De Compostela, Spain - Author
Hosp Gen La Palma, Gastroenterol Dept, Santa Cruz De Tenerife, Spain - Author
Hosp Gen Univ Dr Balmis, Gastroenterol Dept, Inst Invest Sanitaria Biomed de Alicante, Alicante, Spain - Author
Hosp Santa Barbara, Gastroenterol Dept, Soria, Spain - Author
Hosp Univ Cabuenes, Gastroenterol Dept, Gijon, Spain - Author
Hosp Univ Canarias, Gastroenterol Dept, San Cristobal la Laguna, Spain - Author
Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias, Gastroenterol Dept, Oviedo, Spain - Author
Hosp Univ Germans Trias I Pujol, Gastroenterol Dept, Badalona, Spain - Author
Hosp Univ Marques Valdecilla, Inst Invest Sanitaria Valdecilla, Gastroenterol Dept, Santander, Spain - Author
Hosp Univ Miguel Servet, Gastroenterol Dept, Zaragoza, Spain - Author
Hosp Univ Navarra, Inst Invest Sanitaria Navarra IdiSNA, Gastroenterol Dept, Pamplona, Spain - Author
Hosp Univ Nuestra Senora Candelaria, Gastroenterol Dept, Santa Cruz De Tenerife, CA, Spain - Author
Hosp Univ Ramon & Cajal, Gastroenterol Dept, Madrid, Spain - Author
Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba, Gastroenterol Dept, Cordoba, Spain - Author
Hosp Univ San Agustin, Gastroenterol Dept, Aviles, Spain - Author
Hosp Univ Torrejon, Gastroenterol Dept, Madrid, Spain - Author
Hosp Univ Virgen de Ias Nieves, Gastroenterol Dept, Granada, Spain - Author
Hosp Univ Virgen Rocio, Gastroenterol Dept, Seville, Spain - Author
Hosp Virgen La Luz, Gastroenterol Dept, Cuenca, Spain - Author
Hospital Clínico Universitario de Santiago - Author
Hospital Clínico Universitario Lozano Blesa - Author
Hospital de Montilla - Author
Hospital de Santa Bárbara de Soria - Author
Hospital General de La Palma - Author
Hospital General Universitario de Alicante - Author
Hospital General Universitario de Valencia - Author
Hospital Miguel Servet - Author
Hospital Universitari Germans Trias i Pujol - Author
Hospital Universitario Central de Asturias - Author
Hospital Universitario de Cabueñes - Author
Hospital Universitario de Canarias - Author
Hospital Universitario de Torrejón - Author
Hospital Universitario Marqués de Valdecilla - Author
Hospital Universitario Nuestra Senora de Candelaria - Author
Hospital Universitario Ramón y Cajal - Author
Hospital Universitario Reina Sofía - Author
Hospital Universitario San Agustín - Author
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO - Author
Hospital Virgen de La Luz de Cuenca - Author
Instituto de Investigación Sanitaria Hospital Universitario de La Princesa - Author
Osakidetza, Donostia University Hospital - Author
Univ Autonoma Madrid, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa, CIBEREHD,Gastroenterol Dept, Madrid, Spain - Author
Univ Pais Vasco UPV EHU, Hosp Univ Donostia, Inst Biodonostia, Gastroenterol Dept, Donostia San Sebastian, Spain - Author
Universidad de Navarra - Author
See more

Abstract

Background and Aims: Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was to compare the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained ADA originator vs. those who switched to ADA biosimilar. Methods: Patients receiving ADA originator who were in clinical remission at standard dose of ADA originator were included. Patients who maintained ADA originator formed the non-switch cohort (NSC), and those who switched to different ADA biosimilars constituted the switch cohort (SC). Clinical remission was defined as a Harvey–Bradshaw index ≤4 in Crohn's disease and a partial Mayo score ≤2 in ulcerative colitis. To control possible confounding effects on treatment discontinuation, an inverse probability treatment weighted proportional hazard Cox regression was performed. Results: Five hundred and twenty-four patients were included: 211 in the SC and 313 in the NSC. The median follow-up was 13 months in the SC and 24 months in the NSC (p < 0.001). The incidence rate of ADA discontinuation was 8% and 7% per patient-year in the SC and in the NSC, respectively (p > 0.05). In the multivariate analysis, switching from ADA originator to ADA biosimilar was not associated with therapy discontinuation. The incidence rate of relapse was 8% per patient-year in the SC and 6% per patient-year in the NSC (p > 0.05). Six percent of the patients had adverse events in the SC vs. 5% in the NSC (p > 0.05). Conclusion: Switching to ADA biosimilar did not impair patients' outcomes in comparison with maintaining on the originator.

Keywords

biosimilarinflammatory bowel diseaseinfliximabmaintenancesafetyAdalimumabAntibodies, monoclonalBiosimilarBiosimilar pharmaceuticalsDrug substitutionGastrointestinal agentsHumansInflammatory bowel diseaseInflammatory bowel diseasesInfliximabSb5Treatment outcome

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal ALIMENTARY PHARMACOLOGY & THERAPEUTICS due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 21/354, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 9.56, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 5
  • Scopus: 6
  • Europe PMC: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 15.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 19 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 15.75.
  • The number of mentions on the social network X (formerly Twitter): 24 (Altmetric).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Granada.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Casanova MJ) .

the author responsible for correspondence tasks has been Casanova MJ.